ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Channel Therapeutics Corporation (CHRO) shows an Average True Range (ATR) of 0.17 and an Enterprise Value of N/A. Its average trading volume over the past 3 months is 33.23K, indicating liquidity. These fundamental metrics provide insight into CHRO's underlying financial health and market activity.
Channel Therapeutics Corporation (CHRO) technical indicators as of August 1, 2025: the SMA 20 is 11.46%, SMA 50 at 15.97%, and SMA 200 at 16.57%. The RSI 14 value is 60.89, suggesting its current momentum. These technical analysis signals help assess CHRO's price trends and potential future movements.
Channel Therapeutics Corporation (CHRO) stock performance overview as of August 1, 2025: The 52-week high is $38 (currently -64.47% below), and the 52-week low is $4.5 (currently 200% above). Over the past year, CHRO's performance is 2.27%, compared to the S&P 500's 14.84% change.
According to market data, Channel Therapeutics Corporation (CHRO) stock's recent performance metrics show that over the last month, CHRO is 42.11%, with a Year-to-Date (YTD) performance of 110.61%. Over the past year, the stock has seen a 2.27% change. These figures summarize CHRO's price movements across various periods, reflecting its historical returns.
According to current financial data, CHRO stock's P/E (TTM) ratio is -1.12, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for CHRO, including P/S (N/A), P/B (-1.97), and P/FCF (-2.01), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.